ABVD
ABVD
ABVD is a chemotherapy regimen used in the treatment of Hodgkin lymphoma. The acronym ABVD stands for the drugs used in the treatment: Adriamycin, Bleomycin, Vinblastine, and Dacarbazine.
History
The ABVD treatment regimen was first introduced in the 1970s as a less toxic alternative to the then-standard MOPP regimen. It has since become the standard treatment for Hodgkin lymphoma in many countries.
Treatment
The ABVD regimen is typically administered every two weeks for a total of six to eight cycles. Each cycle consists of two treatments, meaning the full course of therapy lasts between three and four months. The drugs are administered intravenously, usually in an outpatient setting.
Side Effects
Like all chemotherapy regimens, ABVD has potential side effects. These can include nausea, vomiting, hair loss, and fatigue. More serious side effects can include lung damage (from bleomycin) and heart damage (from adriamycin). Regular monitoring is required to manage these risks.
Effectiveness
ABVD is considered highly effective in treating Hodgkin lymphoma, with cure rates of over 80% in early-stage disease and over 70% in advanced-stage disease. However, the effectiveness can vary depending on the individual patient's characteristics and the specific subtype of Hodgkin lymphoma.
See Also
External links
- Medical encyclopedia article on ABVD
- Wikipedia's article - ABVD
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski